analysis provides additional support for the neoadjuvant
Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) showed higher rates of invasive-disease-free survival and overall survival as compared to trastuzumab (Herceptin) alone for patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy, as demonstrated in results from the KATHERINE trial (NCT01772472).1
“This prespecified long-term follow-up analysis provides additional support for the neoadjuvant therapy paradigm by showing that adjuvant T-DM1 also provided a significant improvement in overall survival and no evidence of long-term safety issues,” wrote KATHERINE investigators in The New England Journal of Medicine.
https://popl.co/card/uakE9TdV/1
https://popl.co/card/LUeYQpoB/1
https://popl.co/card/B16ExGEu/1
https://popl.co/card/gqNueOzD/1
https://popl.co/card/CcBbyHua/1
https://popl.co/card/31AqpJfl/1
https://popl.co/card/bGgIdLom/1
https://popl.co/card/yy7S79FX/1
https://popl.co/card/NCKsYqCI/1
https://popl.co/card/lO3skO8g/1
https://popl.co/card/atnHzPYL/1
https://popl.co/card/6Y7NZ1sM/1
https://popl.co/card/TrJSJWhk/1
https://popl.co/card/WjUpYALZ/1
https://popl.co/card/u1upqViL/1
https://popl.co/card/Ruh03POU/1
https://popl.co/card/aWyC0O55/1
https://plicik36wik.graphy.com/s/pages/thap-cuong-thi-full
https://plicik36wik.graphy.com/s/pages/anh-khong-dau-full
https://plicik36wik.graphy.com/s/pages/nghi-le-truc-quy-full
https://papaly.com/categories/share?id=4e268d7641dc417b87da87cf0baebd04
https://pinshape.com/users/7428488-bernarhukoohhsg
https://my.workee.net/udu8ehdjjzs-iudf89hxzhj-gdhjoidu